Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou, 310006, China.
Zhejiang University School of Medicine, Hangzhou, 310000, Zhejiang, China.
Cell Mol Immunol. 2024 Nov;21(11):1296-1308. doi: 10.1038/s41423-024-01215-0. Epub 2024 Sep 19.
Hepatocellular carcinoma (HCC) is a highly malignant tumor with significant global health implications. The role of CD4 T cells, particularly conventional CD4 T cells (Tconvs), in HCC progression remains unexplored. Furthermore, epigenetic factors are crucial in immune regulation, yet their specific role in HCC-infiltrating Tconv cells remains elusive. This study elucidates the role of MATR3, an epigenetic regulator, in modulating Tconv activity and immune evasion within the HCC microenvironment. Reanalysis of the scRNA-seq data revealed that early activation of CD4 T cells is crucial for establishing an antitumor immune response. In vivo and in vitro experiments revealed that Tconv enhances cDC1-induced CD8 T-cell activation. Screening identified MATR3 as a critical regulator of Tconv function, which is necessary for antitumour activity but harmful when overexpressed. Excessive MATR3 expression exacerbates Tconv exhaustion and impairs function by recruiting the SWI/SNF complex to relax chromatin in the TOX promoter region, leading to aberrant transcriptional changes. In summary, MATR3 is an HCC-specific epigenetic checkpoint that bidirectionally regulates Tconv antitumour immunity, suggesting new therapeutic strategies targeting epigenetic regulators to enhance antitumour immunity in HCC.
肝细胞癌(HCC)是一种高度恶性肿瘤,对全球健康有重大影响。CD4 T 细胞,特别是传统 CD4 T 细胞(Tconvs)在 HCC 进展中的作用仍未被探索。此外,表观遗传因素在免疫调节中至关重要,但它们在 HCC 浸润性 Tconv 细胞中的具体作用仍不清楚。本研究阐明了表观遗传调节剂 MATR3 在调节 HCC 微环境中 Tconv 活性和免疫逃逸中的作用。对 scRNA-seq 数据的重新分析表明,CD4 T 细胞的早期激活对于建立抗肿瘤免疫反应至关重要。体内和体外实验表明,Tconv 增强 cDC1 诱导的 CD8 T 细胞激活。筛选发现 MATR3 是 Tconv 功能的关键调节剂,它是抗肿瘤活性所必需的,但过度表达时则有害。过度表达 MATR3 会加剧 Tconv 衰竭,并通过招募 SWI/SNF 复合物来松弛 TOX 启动子区域的染色质,导致异常的转录变化,从而损害其功能。总之,MATR3 是一种 HCC 特异性的表观遗传检查点,它双向调节 Tconv 的抗肿瘤免疫,提示针对表观遗传调节剂的新治疗策略,以增强 HCC 中的抗肿瘤免疫。